NMIN Lectures

During the inaugural NMIN Lecture, Dr. Pieter Cullis recounted the history of the research that led to the lipid nanoparticle (LNP) delivery system enabling the Pfizer/BioNTech COVID-19 vaccine, and discussed why being a scientific entrepreneur was vital to this success.

He also spoke about future opportunities and challenges in nanomedicines, and suggested ways Canada might remain at the forefront of this field.

Tuesday 23 February 2021

9 – 10:00 am PST | 12 – 1:00 pm EST

Dr. Pieter Cullis

The NMIN Lecture Series focuses on the activities and successes of NMIN investigators and/or Network research. These lectures provide opportunities for Network participants and stakeholders to stay up to date with Network research, and promote collaboration between Network labs. Attendance is open to any interested parties.

NMIN

Pieter Cullis Invitational Lecture Series

Biomaterials for the Delivery
of Nucleic Acids, Genome Editing Tools and Cells

Dr. Daniel G. Anderson

Professor of Chemical Engineering, Institute for Medical Engineering and Science, Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT

Daniel G. Anderson is a Professor at the Massachusettes Institute of Technology (MIT) in the Department of Chemical Engineering, Institute for Medical Engineering and Science, Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology.

The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science.

Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 400 papers, patentsand patent applications. These advances have led products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer products space.

Dr. Anderson is a founder of Living Proof, Olivo Labs, Crispr Therapeutics (CRSP), Sigilon Therapeutics, Verseau Therapeutics, Orna, and VasoRx.

Dr. Daniel G. Anderson

The Pieter Cullis Invitational Lecture series features individuals working at the frontiers of nanomedicines research and innovation and showcases remarkable examples of scientific and commercial progress in the field.

NMIN

NMIN Lecture Series

The nanoparticle biological identity & protein corona: Challenges, opportunities, & future research directions

Dr. Warren Chan

Professor, Canada Research Chair in Nanobioengineering & Director, Institute of Biomedical Engineering (BME), University of Toronto

Dr. Chan will discuss the role of the biological identity (e.g. protein corona) in mediating cellular interactions. The presentation will delve in the current state of research and reflect on future research directions and commercial opportunities for this burgeoning area of nanomedicine.

Monday 12 April 2021

1:00 – 2:00 pm PDT | 4:00 – 5:00 pm EDT

Warren Chan, PhD, is Director of the Institute of Biomaterials and Biomedical Engineering; Distinguished Professor of Nanobioengineering; and Canada Research Chair in Nanobioengineering – all at the University of Toronto. He is also an NMIN Principal Investigator in Theme 3: Diagnostics.

Dr. Chan’s Integrated Nanotechnology & Biomedical Sciences Laboratory is interested in studying and understanding the proteomic and genomic changes associated with abnormal cells (e.g., cancer cells or virally-infected cells) and tissues. His lab aims to elucidate the cell’s molecular dynamics by using recent developments in nanotechnology (e.g., inorganic nanostructures), microtechnology (e.g., micro-electromechanical systems and capillary flow systems), and molecular engineering (e.g., phage-display) as well as engineering new instrumentation and techniques to address biological questions. Dr. Chan and colleagues seek a fundamental understanding of molecular processes with technology developments toward the designing of novel diagnostic schemes and therapeutic strategies.

Dr. Warren Chan

Questions: contact Leah Graystone, NMIN Events & HQP Program Coordinator, at: leahgraystone@nanomedicines.ca